Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Big Pharma Split's Enterprise Value is C$13.05 Mil.
Big Pharma Split's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was C$-1.95 Mil. Therefore, Big Pharma Split's EV-to-OCF for today is -6.70.
The historical rank and industry rank for Big Pharma Split's EV-to-OCF or its related term are showing as below:
TSX:PRM'
s EV-to-OCF Range Over the Past 10 Years
Min: -14.46 Med: 1.8 Max: 20.26
Current: -11.03
During the past 9 years, the highest EV-to-OCF of Big Pharma Split was 20.26. The lowest was -14.46. And the median was 1.80.
TSX:PRM's EV-to-OCF is not ranked
in the Asset Management industry.
Industry Median: 6.87
vs TSX:PRM: -11.03
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Big Pharma Split's PE Ratio (TTM) for today is calculated as:
Big Pharma Split's share price for today is C$14.44.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was C$5.428.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Big Pharma Split EV-to-OCF Related Terms
Big Pharma Split EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split EV-to-OCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's EV-to-OCF falls into.
Big Pharma Split's current Enterprise Value is C$13.05 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was C$-1.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a EV-to-OCF of -6.70 as of Sep. 22, 2026.
Is Big Pharma Split's EV-to-OCF too high?
Big Pharma Split's current EV-to-OCF is -6.70. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's EV-to-OCF compare to BLK and BX?
Big Pharma Split's EV-to-OCF of -6.70 can be compared against companies in the Asset Management industry. The industry median EV-to-OCF is 6.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for an Asset Management company?
The median EV-to-OCF among Asset Management companies is 6.87, based on 1,495 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median EV-to-OCF is 6.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current EV-to-OCF is -6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current EV-to-OCF of -6.70. The stock's GF Value™ is C$1.80, compared to a current price of C$14.44 — trading 702.2% above its estimated fair value. The current EV-to-OCF is -6.70. Big Pharma Split's overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current EV-to-OCF is -6.70 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$14.44 is trading 702.2% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
EV-to-OCF: -6.70
GF Value™: C$1.80 vs. price of C$14.44 (702.2% above fair value)
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a Canadian closed-end investment fund corporation listed on the Toronto Stock Exchange. It invests in a portfolio of equity securities of large pharmaceutical companies, primarily those with operations in the United States, France, and the United Kingdom. The fund offers two classes of shares: preferred shares, which receive fixed cumulative preferential quarterly cash distributions, and class A shares, which receive regular monthly cash distributions plus the opportunity for capital appreciation. The fund employs a split-share structure, using the proceeds from preferred share issuance to fund the portfolio while directing dividend income and capital gains to class A shareholders. Its investment strategy focuses on established global pharmaceutical firms with stable dividend-paying histories, and it is managed by Harvest Portfolios Group.
7GF Score
Get the complete analysis for TSX:PRM
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
